TEE
AGRX

Tibra Equities Europe’s Agile Therapeutics AGRX Stock Holding History

Tibra Equities Europe’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-121
Closed -$321K – 230
2021
Q2 		$321K Buy
+121
New +$399K 0.1% 144

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tibra Equities Europe's AGRX Position: Q3 2021 in Review

Tibra Equities Europe sold out of Agile Therapeutics (AGRX) in Q3 2021, closing a stake of 121 shares — an estimated $321K sold.

Tibra Equities Europe first reported a position in AGRX in Q2 2021 and held it in 1 quarter. The position peaked at $321K in Q2 2021. 49 funds tracked by Wall St. Rank hold AGRX as of Q3 2021.

  • Tibra Equities Europe reported no remaining Agile Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 121 Agile Therapeutics shares in Q3 2021, an estimated $321K.
  • Tibra Equities Europe first reported a position in Agile Therapeutics in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Agile Therapeutics position peaked at $321K in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.